First Tracks Biotherapeutics (HAM:B43) Total Liabilities: €48.03 Mil (As of Dec. 2024)


HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €32.00
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Total Liabilities?

First Tracks Biotherapeutics HAM:B43 +29.29% 20 Total Liabilities is €48.03 Mil as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

First Tracks Biotherapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was €48.03 Mil.

First Tracks Biotherapeutics's quarterly Total Liabilities increased from . 20 (€0.00 Mil) to Dec. 2023 (€31.42 Mil) and increased from Dec. 2023 (€31.42 Mil) to Dec. 2024 (€48.03 Mil).

First Tracks Biotherapeutics's annual Total Liabilities increased from . 20 (€0.00 Mil) to Dec. 2023 (€31.42 Mil) and increased from Dec. 2023 (€31.42 Mil) to Dec. 2024 (€48.03 Mil).

First Tracks Biotherapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Total Liabilities Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Total Liabilities
31.42 48.03

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Total Liabilities 31.42 48.03
HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

First Tracks Biotherapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=34.555+(13.477+-3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=48.03

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=422.006-373.974
=48.03

First Tracks Biotherapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=34.555+(13.477+-3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=48.03

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=422.006-373.974
=48.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €48.03 Mil mean?
First Tracks Biotherapeutics (HAM:B43) has a Total Liabilities of €48.03 Mil as of Dec. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Total Liabilities too high?
First Tracks Biotherapeutics' current Total Liabilities is €48.03 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Total Liabilities compare to ALT and RGNX?
First Tracks Biotherapeutics' Total Liabilities of €48.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Total Liabilities is €48.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current Total Liabilities of €48.03 Mil. The current Total Liabilities is €48.03 Mil. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current Total Liabilities is €48.03 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price